SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Anti-PTK7 Antibody, Biotin-Labeled

Catalog: 102726
Lot: 250521

Product Information

Description:	Recombinant human anti-PTK7 antibody recognizing human PTK7 (Protein Tyrosine Kinase 7) protein. This anti-PTK7 antibody is a purified, humanized recombinant monoclonal antibody, which contains an Avi-Tag™ and is biotinylated at the C-terminus of the heavy chain unit. This antibody has been tested in a binding assay. This antibody is similar to Cofetuzumab.
Background:	PTK7 (Protein Tyrosine Kinase 7) is a pseudokinase of the receptor tyrosine kinase (RTK) family and shares a common ligand (Wnt5a) with fellow pseudokinases ROR1 (receptor tyrosine kinase-like orphan receptor 1) and ROR2. Despite the lack of a functional kinase domain, PTK7 still contributes to downstream signaling of Wnt5a through its interaction with LRP6 (low-density lipoprotein receptor-related protein 6) and FZD (frizzled) receptors. PTK7 expression contributes to oncogenic potential in a variety of solid tumors including ovarian, colorectal and breast cancers and neuroblastoma. The cell surface expression and oncogenic function of PTK7 in a variety of tumor types makes it a compelling target for both CAR (chimeric antigen receptor)-T cell and antibody based therapeutic development. The use of cofetuzumab pelidotin, an ADC (antibody-drug conjugate) based on auristatin and targeting PTK7, showed promise in the treatment of ovarian cancer, NSCLC (non-small cell lung cancer) and TNBC (triple-negative breast cancer), confirming the potential of targeting PTK7 in oncology.
Species:	Human
Isotype:	IgG1
Clonality:	Monoclonal
Concentration:	1.59 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	Heavy chain: 51 kDa + glycans; Light chain: 24 kDa
Glycosylation:	This antibody runs at a higher MW by SDS-PAGE due to glycosylation.
Label:	This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation confirmed to be ≥90%.
Endotoxin Level:	4.4 EU/mg
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	A white 96-well plate was precoated with PTK7, His-Tag protein (AcroBiosystems # PT7-H52H3) (100 ng/well). Blocking Buffer 3 (#79743) and PBST were used for blocking and washing steps, respectively. For protein titration a serial dilution of Anti-PTK7 Antibody, Biotin-Labeled (#102726) at the highest concentration of 4 ng/µl (200 ng/reaction) was prepared in 1x PP-02 Assay Buffer (#82620). Diluted Anti-PTK7 was then added to the wells and plate was incubated at Room Temperature (RT) for 1 hour. The plate was then washed again and incubated with anti-Fc-HRP conjugate diluted 1:1000 in Blocking Buffer 3 for 1 hour at RT. After the final wash, ELISA ECL mix (#79670) was added to each well and chemiluminescence was read.
Applications:	Useful for binding assays.

Anti-PTK7 Antibody, Biotin-Labeled

Catalog: 102726
Lot: 250521

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



Anti-PTK7:PTK7 Binding Activity



Biotin-Avidin Pulldown



1. Beads
2. Flow Thru
3. Control
4. Standards

99% biotin labeled.
* Avidin from beads.